Lee MK

References (7)

Title : A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naive patients with type 2 diabetes - Yang_2015_Endocr.J_62_449
Author(s) : Yang HK , Min KW , Park SW , Chung CH , Park KS , Choi SH , Song KH , Kim DM , Lee MK , Sung YA , Baik SH , Kim IJ , Cha BS , Park JH , Ahn YB , Lee IK , Yoo SJ , Kim J , Park Ie B , Park TS , Yoon KH
Ref : Endocrine Journal , 62 :449 , 2015
Abstract : The aim of this study was to evaluate the efficacy and safety of anagliptin in drug-naive patients with type 2 diabetes in a double-blind randomized placebo-controlled study. A total of 109 patients were randomized to 100 mg (n=37) or 200 mg (n=33) anagliptin twice daily or placebo (n=39). The primary objective was to alter HbA1c levels from baseline at a 24-week endpoint. The overall baseline mean age and body mass index were 56.20 +/- 9.77 years and 25.01 +/- 2.97 kg/m(2), respectively, and the HbA1c level was of 7.14 +/- 0.69 %. Anagliptin at 100 mg and 200 mg produced significant reductions in HbA1c (-0.50 +/- 0.45 % and -0.51 +/- 0.55%, respectively), and the placebo treatment resulted in an increase in HbA1c by 0.23 +/- 0.62 %. Both doses of anagliptin produced significant decreases in fasting plasma glucose (-0.53 +/- 1.25 mmol/L and -0.72 +/- 1.25 mmol/L, respectively) and the proinsulin/insulin ratio (-0.04 +/- 0.15 and -0.07 +/- 0.18, respectively) compared with placebo. No meaningful body weight changes from baseline were observed in three groups. Plasma dipeptidyl peptidase (DPP)-4 activity was significantly inhibited after 24 weeks of anagliptin treatment, and >75% and >90% inhibitions were observed during the meal tolerance tests with 100 mg and 200 mg anagliptin, respectively. The incidences of adverse or serious adverse events were similar among the three study groups. Twice-daily anagliptin therapy effectively inhibited DPP-4 activity and improved glycemic control and was well-tolerated in patients with type 2 diabetes.
ESTHER : Yang_2015_Endocr.J_62_449
PubMedSearch : Yang_2015_Endocr.J_62_449
PubMedID: 25819061

Title : Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension - Jin_2015_Diabetes.Obes.Metab_17_511
Author(s) : Jin SM , Park SW , Yoon KH , Min KW , Song KH , Park KS , Park JY , Park IB , Chung CH , Baik SH , Choi SH , Lee HW , Lee IK , Kim DM , Lee MK
Ref : Diabetes Obes Metab , 17 :511 , 2015
Abstract : We conducted a 24-week, multicentre, double-blind, randomized study with a 28-week extension to compare the efficacy and safety of anagliptin and sitagliptin as an add-on to metformin in patients with type 2 diabetes. Patients inadequately controlled on metformin were randomized to either anagliptin (100 mg twice daily, n = 92) or sitagliptin (100 mg once daily, n = 88). The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline to week 24. The mean changes in HbA1c were -0.85 +/- 0.70% (p < 0.0001) for anagliptin and -0.83 +/- 0.61% (p < 0.0001) for sitagliptin, with a mean difference of -0.02% (95% confidence interval of difference, -0.22 to 0.18%). In both groups, the fasting proinsulin : insulin ratio significantly decreased from baseline, with improved insulin secretion. Safety profiles were similar in each group. In conclusion, the non-inferiority of the efficacy of anagliptin to sitagliptin as an add-on therapy was established with regard to efficacy and safety.
ESTHER : Jin_2015_Diabetes.Obes.Metab_17_511
PubMedSearch : Jin_2015_Diabetes.Obes.Metab_17_511
PubMedID: 25523633

Title : A new pancreatic lipase inhibitor from Broussonetia kanzinoki - Ahn_2012_Bioorg.Med.Chem.Lett_22_2760
Author(s) : Ahn JH , Liu Q , Lee C , Ahn MJ , Yoo HS , Hwang BY , Lee MK
Ref : Bioorganic & Medicinal Chemistry Lett , 22 :2760 , 2012
Abstract : A new phenolic compound, broussonone A (1) were isolated from the stem barks of Broussonetia kanzinoki (Moraceae), together with two diphenylpropanes, broussonin A (2), broussonin B (3), two flavans, 7,4'-dihydroxyflavan (4), 3',7-dihydroxy-4'-methoxyflavan (5), and two flavones, 3,7-dihydroxy-4'-methoxyflavone (6), 3,7,3'-trihydroxy-4'-methoxyflavone (7). Compound 1 showed noncompetitive inhibitory activity on pancreatic lipase with an IC(50) of 28.4 muM. In addition, compounds 1-5 significantly inhibited adipocyte differentiation in 3T3-L1 cells as measured fat accumulation using Oil Red O assay.
ESTHER : Ahn_2012_Bioorg.Med.Chem.Lett_22_2760
PubMedSearch : Ahn_2012_Bioorg.Med.Chem.Lett_22_2760
PubMedID: 22450131

Title : Multi-platform next-generation sequencing of the domestic turkey (Meleagris gallopavo): genome assembly and analysis - Dalloul_2010_PLoS.Biol_8_E1000475
Author(s) : Dalloul RA , Long JA , Zimin AV , Aslam L , Beal K , Blomberg Le A , Bouffard P , Burt DW , Crasta O , Crooijmans RP , Cooper K , Coulombe RA , De S , Delany ME , Dodgson JB , Dong JJ , Evans C , Frederickson KM , Flicek P , Florea L , Folkerts O , Groenen MA , Harkins TT , Herrero J , Hoffmann S , Megens HJ , Jiang A , de Jong P , Kaiser P , Kim H , Kim KW , Kim S , Langenberger D , Lee MK , Lee T , Mane S , Marcais G , Marz M , McElroy AP , Modise T , Nefedov M , Notredame C , Paton IR , Payne WS , Pertea G , Prickett D , Puiu D , Qioa D , Raineri E , Ruffier M , Salzberg SL , Schatz MC , Scheuring C , Schmidt CJ , Schroeder S , Searle SM , Smith EJ , Smith J , Sonstegard TS , Stadler PF , Tafer H , Tu ZJ , Van Tassell CP , Vilella AJ , Williams KP , Yorke JA , Zhang L , Zhang HB , Zhang X , Zhang Y , Reed KM
Ref : PLoS Biol , 8 : , 2010
Abstract : A synergistic combination of two next-generation sequencing platforms with a detailed comparative BAC physical contig map provided a cost-effective assembly of the genome sequence of the domestic turkey (Meleagris gallopavo). Heterozygosity of the sequenced source genome allowed discovery of more than 600,000 high quality single nucleotide variants. Despite this heterozygosity, the current genome assembly ( approximately 1.1 Gb) includes 917 Mb of sequence assigned to specific turkey chromosomes. Annotation identified nearly 16,000 genes, with 15,093 recognized as protein coding and 611 as non-coding RNA genes. Comparative analysis of the turkey, chicken, and zebra finch genomes, and comparing avian to mammalian species, supports the characteristic stability of avian genomes and identifies genes unique to the avian lineage. Clear differences are seen in number and variety of genes of the avian immune system where expansions and novel genes are less frequent than examples of gene loss. The turkey genome sequence provides resources to further understand the evolution of vertebrate genomes and genetic variation underlying economically important quantitative traits in poultry. This integrated approach may be a model for providing both gene and chromosome level assemblies of other species with agricultural, ecological, and evolutionary interest.
ESTHER : Dalloul_2010_PLoS.Biol_8_E1000475
PubMedSearch : Dalloul_2010_PLoS.Biol_8_E1000475
PubMedID: 20838655
Gene_locus related to this paper: melga-g1mv74 , melga-g1myh1 , melga-g1n3b6 , melga-g1n4i8 , melga-g1n8a7 , melga-g1nb53 , melga-g1ndd8 , melga-g1npu5 , melga-g3ur65 , melga-g3uur6 , melga-g1njn8 , melga-g1mrp7 , melga-g1mzw6 , melga-g1n2a7 , melga-g1n608 , melga-g1n2j6 , melga-g1n2k0 , melga-g1ncb6 , melga-g1nei5 , melga-g1n1j3 , melga-g1nfd3 , melga-g1nna9 , melga-h9h0c1 , melga-g1nnl1 , melga-g1nhb9 , melga-g1mtl7 , fical-u3jnn0 , melga-g1n332 , melga-g1mtx9 , melga-g1nns1

Title : Phytophthora genome sequences uncover evolutionary origins and mechanisms of pathogenesis - Tyler_2006_Science_313_1261
Author(s) : Tyler BM , Tripathy S , Zhang X , Dehal P , Jiang RH , Aerts A , Arredondo FD , Baxter L , Bensasson D , Beynon JL , Chapman J , Damasceno CM , Dorrance AE , Dou D , Dickerman AW , Dubchak IL , Garbelotto M , Gijzen M , Gordon SG , Govers F , Grunwald NJ , Huang W , Ivors KL , Jones RW , Kamoun S , Krampis K , Lamour KH , Lee MK , McDonald WH , Medina M , Meijer HJ , Nordberg EK , Maclean DJ , Ospina-Giraldo MD , Morris PF , Phuntumart V , Putnam NH , Rash S , Rose JK , Sakihama Y , Salamov AA , Savidor A , Scheuring CF , Smith BM , Sobral BW , Terry A , Torto-Alalibo TA , Win J , Xu Z , Zhang H , Grigoriev IV , Rokhsar DS , Boore JL
Ref : Science , 313 :1261 , 2006
Abstract : Draft genome sequences have been determined for the soybean pathogen Phytophthora sojae and the sudden oak death pathogen Phytophthora ramorum. Oomycetes such as these Phytophthora species share the kingdom Stramenopila with photosynthetic algae such as diatoms, and the presence of many Phytophthora genes of probable phototroph origin supports a photosynthetic ancestry for the stramenopiles. Comparison of the two species' genomes reveals a rapid expansion and diversification of many protein families associated with plant infection such as hydrolases, ABC transporters, protein toxins, proteinase inhibitors, and, in particular, a superfamily of 700 proteins with similarity to known oomycete avirulence genes.
ESTHER : Tyler_2006_Science_313_1261
PubMedSearch : Tyler_2006_Science_313_1261
PubMedID: 16946064
Gene_locus related to this paper: phyrm-h3ga89 , phyrm-h3gbl6.1 , phyrm-h3gbl6.2 , phyrm-h3gbl7 , phyrm-h3gdd4 , phyrm-h3gl36 , phyrm-h3gq42 , phyrm-h3gx86 , phyrm-h3gyi2 , phyrm-h3gyi3 , phyrm-h3gyi4 , phyrm-h3h292 , phyrm-h3h293 , phyrm-h3h967 , phyrm-h3hcf9 , physp-g4ynp3 , physp-g4yut6 , physp-g4yut8 , physp-g4yw23 , physp-g4zis3 , physp-g4zqe3 , physp-g4zqe4 , physp-g4zqf0 , physp-g4zqn9 , physp-g4zwy9 , physp-g5a582 , physp-g5a583 , physp-g5aav9 , phyrm-h3g9e7 , physp-g4zwu9 , phyrm-h3ggp1 , physp-g4ztq5 , physp-g4zwu8 , physp-g4zwv7 , physp-g4zwv6 , physp-g4zwv0 , physp-g4zwv8 , phyrm-h3gp95 , phyrm-h3g6r5 , physp-g4zwv9 , physp-g5a510 , phyrm-h3glu3 , physp-g5aci1 , phyrm-h3h2d0 , physp-g4ztb2 , physp-g4yg47 , phyrm-h3h2c9 , physp-g4ztb3 , phyrm-h3gvj3 , phyrm-h3gy62 , physp-g4yg46 , physp-g4zdt9 , phyrm-h3gdh5 , physp-g4zm41 , physp-g5abj7 , phyrm-h3gz76 , physp-g5a425 , phyrm-h3h080 , physp-g4ytv0 , phyrm-h3gcw7

Title : Mutant presenilin 2 increases acetylcholinesterase activity in neuronal cells - Nguyen_2005_Arch.Pharm.Res_28_1073
Author(s) : Nguyen HN , Hwang DY , Kim YK , Yoon DY , Kim JH , Lee MS , Lee MK , Yun YP , Oh KW , Hong JT
Ref : Arch Pharm Res , 28 :1073 , 2005
Abstract : A presenilin 2 mutation is believed to be involved in the development of Alzheimer's disease. In addition, transgenic mice with a presenilin 2 mutation have been reported to have learning and memory impairments. In this study, exposing PC12 cells expressing mutant presenilin 2 to 50 microM AP25-35, 30 mM L-glutamate and 50 microM H2O2 caused a significant increase in acetylcholine esterase activity. An in vivo study revealed high levels of this enzyme activity in the mutant presenilin 2 transgenic brains compared with the wild type presenilin 2 transgenic and nontransgenic samples. These results suggest that a mutant presenilin 2-induced neurodegeneration in Alzheimer's disease might be involved in the increase in acetylcholinesterase activity. These findings might help in the development of an appropriate therapeutic intervention targeting mutant presenilin 2-induced Alzheimer's disease.
ESTHER : Nguyen_2005_Arch.Pharm.Res_28_1073
PubMedSearch : Nguyen_2005_Arch.Pharm.Res_28_1073
PubMedID: 16212240

Title : Update of the morbidity experience of employees potentially exposed to chlorpyrifos - Burns_1998_Occup.Environ.Med_55_65
Author(s) : Burns CJ , Cartmill JB , Powers BS , Lee MK
Ref : Occup Environ Med , 55 :65 , 1998
Abstract : OBJECTIVES: Chlorpyrifos, an organophosphate ingredient of several important insecticides, has been manufactured at The Dow Chemical Company for 25 years. A previous morbidity study among employees of The Dow Chemical Company found no increased prevalence of illness or symptoms among employees potentially exposed to chlorpyrifos from 1977 to 1985 compared with matched controls. The purpose of the current study was to update the original study to 1994, thereby increasing the statistical power. METHODS: In the present study, 496 potentially exposed subjects were identified and matched for age, race, sex, pay, and year of hire to 911 control subjects. Morbidity data were abstracted from company medical records. RESULTS: The prevalence of peripheral neuropathy was not significantly increased among this group of employees potentially exposed to chlorpyrifos. Significantly increased prevalence odds ratios were identified for five diagnostic categories: diseases of the ear and mastoid process; acute respiratory infections; other diseases of the respiratory system; general symptoms, signs, and ill defined conditions; and symptoms, signs, and ill defined conditions involving the digestive system. There was a strong association of diagnosis with duration of observation period, indicating that the exposed workers were more likely than unexposed workers to have a diagnosis abstracted from the company medical records due to their longer mean period of follow up. Analyses by exposure classification and mean plasma cholinesterase activity did not show a dose response.
CONCLUSIONS: These data do not support a cause and effect relation of the diagnoses mentioned and exposure to chlorpyrifos.
ESTHER : Burns_1998_Occup.Environ.Med_55_65
PubMedSearch : Burns_1998_Occup.Environ.Med_55_65
PubMedID: 9536166